Menu
Not yet recruiting NCT07671092

Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC

Early Phase I Interventional Metastatic Urothelial Carcinoma Breast Cancer TNBC - Triple-Negative Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: RYZ211/212.
Who it may be relevant to
Registry conditions: Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
New Zealand
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)

Overview

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.

Interventions

  • Diagnostic test RYZ211/212
    Imaging Agent

Primary outcome measures

  • To evaluate the biodistribution of RYZ211 in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC [Time frame: Study duration (1 year)]
  • To evaluate the long biodistribution and radiation absorbed doses in critical organs and tumors, and the effective dose of RYZ212 in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC [Time frame: Study duration (1 year)]

Eligibility criteria

Inclusion criteria

  • Are at least 18 years old at the time of signing the informed consent form (ICF)
  • Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC

Exclusion criteria

  • For Women of Childbearing Potential: Are pregnant or breastfeeding

Note: Additional criteria may apply and will be assessed by the study site

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

New Zealand · 1 center
  • Research Facility — Christchurch

Identifiers

NCT: NCT07671092 · RYZ211-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗